Loading patent…
AssigneePraecis Pharmaceuticals, Inc.
InventorsMark A. Findeis, Kathryn Phillips, Gary L. Olsen, Christopher Self
Estimating the term…
Compounds that modulate natural β amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a β amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a β amyloid peptide, preferably a retro-inverso isomer of Aβ17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.
A compound comprising the structure:
A compound having a structure selected from the group consisting of:
A pharmaceutical composition comprising a pharmaceutically acceptable cater and a therapeutically effective amount of a compound comprising the structure:
A compound comprising the structure:
Dependencies are inferred from the claim text.